What are the Hoehn and Yahr stages for Parkinson disease and how do they guide treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hoehn and Yahr Stages for Parkinson's Disease

The Hoehn and Yahr scale divides Parkinson's disease into 5 stages based on motor disability progression, with stages 1-1.5 representing early unilateral disease, stages 2-3 representing bilateral disease with preserved balance, and stages 4-5 representing severe disability with loss of independent mobility.

The Five Stages

The modified Hoehn and Yahr staging system provides a framework for disease progression 1:

  • Stage 1.0-1.5 (Early Stage): Unilateral symptoms that are mild and do not affect social communications, daily life, or work. Early symptoms and signs are present but short in duration and mild in severity 1.

  • Stage 2-3 (Mid Stage): Bilateral disease with symptoms and signs worsening to the point of affecting social communications, daily life, and work. Postural reflexes remain preserved at stage 2, while stage 3 shows mild-to-moderate bilateral disease with some postural instability but the patient remains physically independent 1, 2.

  • Stage 4-5 (Late/Advanced Stage): Severe clinical symptoms where levodopa preparation is insufficient to maintain daily life. Stage 4 patients require assistance with activities of daily living, while stage 5 patients are wheelchair-bound or bedridden unless aided 1, 3.

How Stages Guide Treatment

Early Stage (H&Y 1-1.5)

For early-stage patients, the treatment objective focuses on symptom control while delaying motor complications. The "agonist first" algorithm remains standard, though undertreatment of motor symptoms must be avoided 4. In younger patients (typically <62-65 years), dopamine agonists are initiated first to delay levodopa exposure and subsequent motor complications 2. For older patients, levodopa may be the first choice given better tolerability and efficacy 2.

The goal is to maintain patients at or below H&Y Stage 2.0 level of disability during off-periods while avoiding adverse effects 2.

Mid Stage (H&Y 2-3)

As bilateral symptoms emerge and affect function, treatment intensification becomes necessary. This typically involves adding levodopa if not already initiated, or optimizing dopamine agonist doses combined with levodopa 1, 2. The focus shifts to managing emerging motor fluctuations and dyskinesias while maintaining functional independence.

Advanced Stage (H&Y 3-5)

When optimized oral levodopa therapy and adjunct therapies are no longer effective in controlling severe motor fluctuations, invasive device-aided therapies should be considered 5. The 2024 European Academy of Neurology/Movement Disorder Society guidelines provide clear evidence for this transition:

  • Subthalamic nucleus deep brain stimulation (STN-DBS) is the most extensively studied intervention, with 5 RCTs demonstrating large improvements in motor impairment, motor fluctuations, and dyskinesia, with sustained effectiveness beyond 15 years 5.

  • Globus pallidus interna (GPi) stimulation can be recommended equally to STN stimulation, though levodopa dosage reduction is minimal compared to STN-DBS 5.

  • Levodopa-carbidopa intestinal gel (LCIG) or continuous apomorphine infusion (CAI) may be considered, with RCTs showing moderate improvements in on-time without troublesome dyskinesia 5.

For advanced-stage patients (H&Y 3-5), aerobic activity provides the largest overall significant improvement in neurocognitive function (Δ=0.2700; p=0.0364), while functional strength activities are most beneficial in early stages (H&Y 1-2) 6.

Disease Progression Patterns

The average rate of progression is approximately 0.4 per year on the Hoehn and Yahr scale, with relatively linear intraindividual progression 3. Non-motor symptom burden increases significantly with advancing stage, with intermediate stage showing 5.89-fold higher odds and advanced stage showing 27.74-fold higher odds of greater non-motor symptom severity compared to early stage 7.

Critical Timing Considerations

Gait parameters deteriorate progressively across stages, with stride speed and stride time showing significant differences from H&Y stage 1, while stride length, width, and turn-around time differ from stage 2, and step height from stage 3 8. Contrary to previous beliefs, levodopa can effectively improve gait parameters, with the most notable improvements in stride speed and turn-around time occurring at H&Y stage 3 8.

Common Pitfalls

Avoid delaying invasive therapies too long in advanced patients—the severely fluctuating patient represents the largest group seeking improvement with device-aided therapies, and these should be considered when oral medications fail to provide adequate on-time 5. Additionally, avoid formulation changes during hospitalization as medication errors occur in up to 89.9% of hospitalized PD patients, with 47.7% of incorrect doses being omitted entirely 9.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.